Cost-utility analysis of enzalutamide for patients with previously treated metastatic castration-resistant prostate cancerPublished in Value in Health, 2014C Vicente, V Babashov, F Husein, F Saad, S Naidoo, S Holmstrom. Value in Health, 17(3), A89–A90, 2014.View on Google ScholarShare on Twitter Facebook LinkedIn Previous Next